Orthokeratology is a method of refractive error correction that uses bespoke gas permeable contact lenses to temporarily alter the corneal curvature. Orthokeratology, also known as ortho-k, corneal refractive therapy (CRT), and nighttime vision correction therapy, is a non-surgical procedure that corrects refractive problems by altering the cornea’s curvature to enhance object visibility.
New York, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Orthokeratology Lens Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06315037/?utm_source=GNW To enable quicker as well as more effective corneal reshaping, modern ortho-K technology reverses geometry designs and uses breathable stiff lens material. This technique, which involves temporary medication, is used to treat myopia, hypermetropia, and other vision-related issues. Myopia, hypermetropia, astigmatism, & presbyopia occurrences are predicted to rise, which will help the industry. Wearing lenses that reduce eye sight issue progression and correct eye sight may sound like a fantasy, but it’s actually a reality. Orthokeratology lenses are not exactly a novel concept. However, these lenses have just recently begun to make significant strides. Due to development of advanced and precise technology, the field of technology is currently really advancing. These tools facilitate and expedite the production of 3D models of the eye’s surface. The enhanced polymer substance that makes hard contact lenses more oxygen permeable is another driving force behind the new technology. But since the pandemic began, there has been a significant change, and many more people are now more likely to have refractive defects. It is anticipated that the move toward online education and the widespread adoption of work-from-home policies by businesses would lead to an increase in peoples’ overall screen time and an increase in refractive errors. Consequently, it is possible to predict that during the upcoming years, the market. The main driver fueling the market expansion is key manufacturers’ increased efforts to introduce new products and obtain regulatory approvals. Additionally, the market is growing significantly because of the increasing burden of patients with refractive defects. COVID-19 Impact Analysis The decrease in patient visits to hospitals & clinics brought about by the COVID-19 pandemic had a marginally negative effect. The outbreak of pandemics that swept the world significantly altered how the health care industry is managed. Nobody has been in a decent physical, mental, or emotional state during the pandemic. The government had declared rigorous internment as the coronavirus was about to break out, and individuals were confined to their houses, which increased screen time. People’s eyesight was impacted by excessive exposure to laptops & personal computers. Despite the difficulties that several industries faced during the pandemic, the worldwide orthokeratology market expanded significantly. Market Growth Factors Increase In Cases Of Myopia & High Myopia Myopia & high myopia are becoming more and more commonplace on a massive level. Myopia is a significant public health issue, and excessive myopia is the second-leading factor in the visual impairment globe. In East Asia, the prevalence of myopia is among a large number of students and affected around half of the urban population. Additionally, because myopia’s visual difficulties begin earlier than other causes of blindness like cataracts, its effects on quality of life are also seen earlier. The cost of eye illnesses in various developed regions is estimated to be in the millions. Myopia prevention, as well as control techniques, are therefore highly sought after on a worldwide scale. Increasing Use Of Laptops & Extended Exposure Digital gadgets such as laptops, tablets, smartphones, and e-readers have become an essential part of everyday life. Most occupations necessitate working on computers for extended periods of time. In addition, the need of staying connected has increased with the rise of social networking sites. A worrying trend has been seen where people turn on their cell phones as soon as they get up and continue their trust with digital screens until they go to bed. In addition, the rising use of digital screens has given rise to a disorder called Computer Vision Syndrome (CVS), which harms the eyes and causes issues with vision. Market Restraining Factors Availability Of Various Alternatives In The Market There are various alternatives available in the market like multifocal contact lenses and atropine eye drops. MiSight lenses are the first type of FDA-approved contact lenses for preventing childhood myopia progression. Children as young as 8 years old may be prescribed these soft, disposable lenses. At night, the lenses are removed after being worn during the day. These lenses include concentric rings that refocus light so that it strikes the retina in a different way, deceiving the eye into not enlarging too much. Although the lenses can correct astigmatism. Product Type Outlook Based on product type, the orthokeratology lens market is segmented into overnight ortho-K lenses and day-time ortho- K lenses. In 2021, overnight ortho-K lenses dominated the orthokeratology lens market with the highest revenue share. This is attributed to the easy availability of overnight ortho-K lenses. In addition, ortho-k lenses are customized contact lenses. The user can wake up with clear vision without the need for glasses or contacts the next day. Ortho K lens softly reshapes the eye overnight. All these factors are supporting market growth in this segment. The main advantage of these lenses is that they are needed to be worn only at night. Indication Outlook On the basis of indication, the orthokeratology lens market is fragmented into myopia, presbyopia, hypermetropia and astigmatism. In 2021, the astigmatism segment covered a significant revenue share in the orthokeratology market. The vision may become distorted or fuzzy if someone has astigmatism, a common condition of the eyes. It occurs when the cornea the transparent outer layer of the eye or lens the inner portion of the eye that aids in eye focus have an abnormal shape. The demand for ortho-k lenses is rising in this segment as spherical ortho-k lenses are available which have the ability to reshape the anterior surface of the cornea. Distribution Channel Outlook By distribution channel, the orthokeratology lens market is classified into hospitals, optometry clinics, ophthalmology clinics and others. In 2021, the North America region witnessed the largest revenue share in the orthokeratology lens market. The increase in the prevalence and incidence of vision errors, as well as the number of qualified specialists, are indicators of the market expansion in this region. Additionally, the market in this region is being driven by the rising awareness of the use of ortho-k lenses, successful compensation policies, and market penetration by key competitors in the region. Regional Outlook Region-wise, the orthokeratology lens market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region witnessed the largest revenue share in the orthokeratology lens market. The increase in the prevalence and incidence of vision errors, as well as the number of qualified specialists, are indicators of the market expansion in this region. Additionally, the market in this region is being driven by the rising awareness of the use of ortho-k lenses, successful compensation policies, and market penetration by key competitors in the region. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Vision Care, Inc.), Bausch Health Companies, Inc., The Cooper Companies, Inc., Euclid Systems Corporation, Alpha Corporation, Inc. (Menicon Co., Ltd.), Brighten Optix Corporation, TruForm Optics, Inc., Art Optical Contact Lens, Inc., and MiracLens, LLC. Strategies deployed in Orthokeratology Lens Market Jun-2022: CooperVision took over EnsEyes, a leader in specialty contact lenses. Under the acquisition, EnsEyes would operate within CooperVision’s Specialty EyeCare group. The acquisition focused on accelerating the growth of specialty lens adoption across these markets. In addition, the acquisition would give its highly respected team more resources for growth, further build the expertise of CooperVision as well as support eye care professionals’ soaring enthusiasm for specialty fitting. Apr-2022: Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design, and distribution pioneer. The acquisition aimed to enhance the abilities of both companies to provide comprehensive specialty contact lens care to more patients worldwide. Jan-2022: Johnson & Johnson introduced ACUVUE Ability, a powerful new comprehensive approach for myopia management. The launch would address the spread and progression of myopia in children. May-2021: CooperVision received European approval for Procornea DreamLite night lenses. The lenses are a new CooperVision myopia control product to gain the CE Mark, joining EyeDream & Paragon CRT ortho-k designs, MiSight 1-day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. May-2021: Euclid Systems released Euclid MAX, the overnight orthokeratology lens. These lenses would gently reshape the cornea to manage myopia while the patient sleeps. The latest contact lenses provide incredible lens stability, oxygen permeability, and wettability, which adds a layer of comfort, safety, and satisfaction to my Ortho-K practice. Feb-2021: CooperCompanies formed a joint venture with EssilorLuxottica, a leader in the design, manufacture, and distribution of ophthalmic lenses. The companies are focused on accelerating the commercialization of innovative spectacle lenses from SightGlass Vision, which is developed to reduce the progression of myopia in children. With the SightGlass Vision technology by this collaboration, MiSight 1 day and orthokeratology contact lenses from CooperVision, and Stellest lenses from Essilor, ECPs can create a comprehensive optical intervention portfolio to address the rising number of children impacted by myopia. Sep-2020: TruForm Optics took over DreamLens. The acquisition would enable licensed eye care professionals to expand the options of managing myopia using DreamLens, manufactured in Boston Equalens II material, after achieving online certification. May-2020: Bausch + Lomb unveiled LuxSmart, an Extended Depth of Focus intraocular lens (IOL), and LuxGood, a new monofocal IOL. These products feature the latest premium optic design and PRO technology that decreases dysphotopsia, a common phenomenon that can occur in some premium IOLs and compromise a patient’s vision. Scope of the Study Market Segments covered in the Report: By Product Type • Overnight Ortho-K lenses • Day-time Ortho- K lenses By Indication • Myopia • Presbyopia • Hypermetropia • Astigmatism By Distribution Channel • Ophthalmology Clinics • Optometry Clinics • Hospitals • Others By Geography • North America o US o Canada o Mexico o Rest of North America • Europe o Germany o UK o France o Russia o Spain o Italy o Rest of Europe • Asia Pacific o China o Japan o India o South Korea o Singapore o Malaysia o Rest of Asia Pacific • LAMEA o Brazil o Argentina o UAE o Saudi Arabia o South Africa o Nigeria o Rest of LAMEA Companies Profiled • Johnson & Johnson (Johnson & Johnson Vision Care, Inc.) • Bausch Health Companies, Inc. • The Cooper Companies, Inc. • Euclid Systems Corporation • Alpha Corporation, Inc. (Menicon Co., Ltd.) • Brighten Optix Corporation • TruForm Optics, Inc. • Art Optical Contact Lens, Inc. • MiracLens, LLC Unique Offerings • Exhaustive coverage • Highest number of market tables and figures • Subscription based model available • Guaranteed best price • Assured post sales research support with 10% customization free Read the full report: https://www.reportlinker.com/p06315037/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.
U.S. based monkeypox vaccine manufacturer targets December for first batch of doses for delivery.
The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.
The U.S. government asks Bavarian Nordic, the sole manufacturer of a monkeypox vaccine, to find new partners.
As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances. It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development. Meanwhile, Sarepta Therapeutics currently boasts over 37 pipeline programs, including 21 assets in gene therapy alone.
The drug, which can take effect within a week, uses a different mechanism than traditional treatments for depression.
NBC News Chief Foreign Correspondent Richard Engel announced Thursday that his son Henry, 6, has died. “Our beloved son Henry passed away.
Get ready for a big change in how the U.S. will pay for COVID-19 vaccines and treatments. The Department of Health and Human Services is expected to hold a meeting later this month with drug makers, pharmacies, and state health departments to discuss moving coverage of pandemic therapies away from the U.S. government and into a commercial market, according to The Wall Street Journal. Arpa Garay, Moderna’s (MRNA) chief commercial officer, told investors on a recent earnings call that the company is already preparing for the evolution of the COVID-19 vaccine market.
The ads are everywhere — as are the inflated claims: Special shampoos and treatments, sometimes costing thousands of dollars, will make hair grow. But many dermatologists who specialize in hair loss say that most of these products do not work. “There is an endless array of useless hair-growth remedies,” often at “significant cost,” said Dr. Brett King, a dermatologist at Yale School of Medicine. Yet, he added, “because people are desperate, such hair growth remedies continue to abound.” But ther
Verve’s effort to lower patients’ levels of bad cholesterol with a single injection is gradually making clinical progress and would be a significant upgrade from statins and other medicines currently available.
The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.
These three first aid essentials will keep everyone healthy and feeling good while you enjoy the summer.
White House coronavirus response coordinator Ashish Jha said Wednesday evening that updated COVID-19 vaccines are expected to be available in “a few short weeks” for everyone over the age of 12. “The vaccines that are coming in a few short weeks are specifically designed for the virus that’s out there, and I believe it’s…
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Second Quarter 2022 Operational and Financial Results On August 16, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 2Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcast were hosted later that morning. Key highlights since the previous update in May
“I have eaten them my entire life, and will continue. But you are putting yourself at risk when you do it,” restaurant manager says
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
If approved, the Pittsburgh-based firm's treatment would help patients with a rare skin disease.
Medicare beneficiaries are in for some big savings under the Inflation Reduction Act, which is ushering in a new era of negotiating drug prices and capping out-of-pocket expenses. The Inflation Reduction Act has a few key components that specifically target the needs of the older Americans Medicare covers — three will be effective at the beginning of 2023, and the rest in a few years. Biden signed the Inflation Reduction Act earlier this week–it is considered a major win for Democrats with its focus on healthcare spending, climate change and corporate taxation.
Sanofi's run of bad luck continued Wednesday after the company scrapped a failed breast cancer drug, leading Sanofi stock to crumble.
bluebird bio developed the therapy to treat the blood disorder beta-thalassemia. Existing treatments are even more expensive.